272 related articles for article (PubMed ID: 9021203)
41. Piperacillin/tazobactam and ticarcillin/clavulanic acid against resistant Enterobacteriaceae.
Kempers J; MacLaren DM
J Antimicrob Chemother; 1990 Oct; 26(4):598-9. PubMed ID: 2174855
[No Abstract] [Full Text] [Related]
42. Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa.
Lemmen SW; Zolldann D; Klik S; Lütticken R; Kümmerer K; Häfner H
Chemotherapy; 2004 Apr; 50(1):27-30. PubMed ID: 15084802
[TBL] [Abstract][Full Text] [Related]
43. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Kotapati S; Kuti JL; Nicolau DP
Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
[TBL] [Abstract][Full Text] [Related]
44. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.
Strayer AH; Gilbert DH; Pivarnik P; Medeiros AA; Zinner SH; Dudley MN
Antimicrob Agents Chemother; 1994 Oct; 38(10):2351-6. PubMed ID: 7840569
[TBL] [Abstract][Full Text] [Related]
45. In vitro anaerobic data on ticarcillin/clavulanate. A review of an ongoing survey.
Sanders CV; Aldridge KE
J Reprod Med; 1990 Mar; 35(3 Suppl):313-6. PubMed ID: 2319513
[TBL] [Abstract][Full Text] [Related]
46. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.
Jacobs MR; Aronoff SC; Johenning S; Yamabe S
J Antimicrob Chemother; 1986 Aug; 18(2):177-84. PubMed ID: 3019984
[TBL] [Abstract][Full Text] [Related]
47. Beta-lactamase inhibitors: relation between kinetic data and in-vitro synergism studies.
Cullmann W
Zentralbl Bakteriol; 1991 Oct; 275(4):500-3. PubMed ID: 1661596
[TBL] [Abstract][Full Text] [Related]
48. In-vitro susceptibility of the Bacteroides fragilis group to cefoperazone, ampicillin, ticarcillin and amoxycillin combined with beta-lactamase inhibitors.
Barry AL; Jones RN; Packer RR
J Antimicrob Chemother; 1986 Jan; 17(1):125-7. PubMed ID: 3005222
[No Abstract] [Full Text] [Related]
49. Bactericidal activity of low-dose ceftizoxime plus metronidazole compared with cefoxitin and ampicillin-sulbactam.
Freeman CD; Nightingale CH; Nicolau DP; Belliveau PP; Tessier PR; Fu Q; Xuan DW; Quintiliani R
Pharmacotherapy; 1994; 14(2):185-90. PubMed ID: 8197037
[TBL] [Abstract][Full Text] [Related]
50. Clavulanic acid in combination with ticarcillin: an in-vitro comparison with other beta-lactams.
Clarke AM; Zemcov SJ
J Antimicrob Chemother; 1984 Feb; 13(2):121-8. PubMed ID: 6323375
[TBL] [Abstract][Full Text] [Related]
51. Beta-lactamase inhibitors and Acinetobacter spp.
Eng RH; Smith SM; Cherubin CE
J Antimicrob Chemother; 1990 Sep; 26(3):449-51. PubMed ID: 2172200
[No Abstract] [Full Text] [Related]
52. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S
J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820
[TBL] [Abstract][Full Text] [Related]
54. In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria.
Kitzis MD; Ferré B; Coutrot A; Acar JF; Gutmann L
Eur J Clin Microbiol Infect Dis; 1989 Sep; 8(9):783-8. PubMed ID: 2556277
[TBL] [Abstract][Full Text] [Related]
55. In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures.
Valéria Dos Santos K; Diniz CG; Coutinho SC; Apolônio ACM; Geralda de Sousa-Gaia L; Nicoli JR; Farias LM; Roque de Carvalho MA
J Med Microbiol; 2007 Jun; 56(Pt 6):798-802. PubMed ID: 17510265
[TBL] [Abstract][Full Text] [Related]
56. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli.
Blazquez J; Baquero MR; Canton R; Alos I; Baquero F
Antimicrob Agents Chemother; 1993 Oct; 37(10):2059-63. PubMed ID: 8257123
[TBL] [Abstract][Full Text] [Related]
57. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.
Appelbaum PC
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():29-38. PubMed ID: 8383654
[TBL] [Abstract][Full Text] [Related]
58. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
Nord CE
J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
[No Abstract] [Full Text] [Related]
59. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Ong CT; Kuti JL; Nicolau DP;
Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
[TBL] [Abstract][Full Text] [Related]
60. Use of beta-lactam/beta-lactamase-inhibitor combinations as antimycobacterial agents.
Prabhakaran K; Harris EB; Randhawa B; Adams LB; Williams DL; Hastings RC
Microbios; 1993; 76(309):251-61. PubMed ID: 8302203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
